News

August 4, 2020

Announcing our $20M Series A Financing to Bring Precision Radioligand Therapy to Cancer Patients

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits ...

June 23, 2020

ITM and POINT Biopharma Sign Two Supply Agreements for No-carrier-added Lutetium-177

ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of ...

May 26, 2020

POINT Biopharma to Launch First US Manufacturing Facility in Indiana

POINT Biopharma (POINT) announced plans today to establish its first U.S. manufacturing facility in Indianapolis. “Indiana has established itself as a global leader in life sciences, ranking second in the nation for total exports," Go...

May 24, 2020

POINT Biopharma Announces Manufacturing Leadership and Search for US manufacturing site

POINT Biopharma Inc. today announced the appointment of Todd Hockemeyer as Executive Vice President of US Manufacturing Operations. An industrial engineer, with operations and manufacturing expertise spanning over 25 years, Hockemeyer...

May 12, 2020

POINT Biopharma Announces Phase 3 Prostate Cancer Trial

POINT Biopharma Inc. is pleased to announce the selection of PSI CRO to manage its phase 3 clinical study of PNT2002, a 177Lu-PSMA radiotherapeutic for the treatment of metastatic castrate-resistant prostate cancer.“PSI CRO is a leading...